| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | RAF265 | FIMM | pan-cancer | AAC | -0.033 | 0.9 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0066 | 0.9 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | -0.0067 | 0.9 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | 0.0064 | 0.9 |
| mRNA | betulinic acid | CTRPv2 | pan-cancer | AAC | 0.0071 | 0.9 |
| mRNA | KU 0060648 | CTRPv2 | pan-cancer | AAC | -0.0065 | 0.9 |
| mRNA | paclitaxel | GDSC1000 | pan-cancer | AAC | 0.009 | 0.9 |
| mRNA | BI-2536 | CTRPv2 | pan-cancer | AAC | 0.0056 | 0.9 |
| mRNA | Sorafenib | FIMM | pan-cancer | AAC | -0.03 | 0.9 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | -0.0079 | 0.9 |